Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937099 · ClinicalTrials.gov registry record · Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
A Phase 3 study of Crohn's Disease and Obesity or Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT06937099: Recruiting Phase 3 study of Crohn's Disease and Obesity or Overweight, sponsored by Eli Lilly and Company.
NCT06937099 is a Phase 3 study of Crohn's Disease and Obesity or Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 290 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937099, a Phase 3 study of Crohn's Disease and Obesity or Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Primary Outcome
Percentage of participants who simultaneously achieve clinical remission by CDAI, endoscopic remission and at least 10% weight reduction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG Mirikizumab
Study Locations (20)
Florida
- Research Associates of South Florida - Miami - Southwest 8th Street - Miami
- Gastro Health Research - Miami - Miami
- Orlando Health - Orlando
- Digestive and Liver Center of Florida - Orlando
- Gastro Health Research - Pensacola - Pensacola
- Precision Clinical Research - Sunrise
California
- Smart Cures Clinical Research - Anaheim
- Cedars-Sinai Medical Center - Beverly Hills
- United Medical Doctors - Los Alamitos - Los Alamitos
- California Medical Research Associates - Northridge
Indiana
- Indiana University Health University Hospital - Indianapolis
- Gastroenterology Health Partners - New Albany
Louisiana
- Care Access - New Iberia - New Iberia
- Louisiana Research Center - Shreveport
Alabama
- Digestive Health Specialists - Dothan
Idaho
- Grand Teton Research Group - Idaho Falls
Illinois
- Rush University Medical Center - Chicago
Kentucky
- Gastroenterology Health Partners - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
What NCT06937099 shows while recruiting
NCT06937099 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06937099 names 20 study sites across 10 states, led by Florida, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06937099 about?
NCT06937099 is a clinical study titled "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight". The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6...
What is the current status of trial NCT06937099?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2025-06-26. Estimated completion is 2028-05.
What conditions does trial NCT06937099 study?
This clinical trial studies the following conditions: Crohn's Disease, Obesity or Overweight.
What interventions are being tested in trial NCT06937099?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06937099?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937099 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06937099's enrollment target sits among peer trials
290 41st of 105 higher than 65 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI